Get the Stockscreener App
9.61
2.14%
-0.21
Satellos Bioscience Inc stock is traded at $9.61, with a volume of 37,647.
It is down -2.14% in the last 24 hours and up +6.72% over the past month.
Satellos Bioscience Inc is a Canadian biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation, which Satellos has identified as a root cause of the progressive nature of this disease.
See More
Previous Close:
$9.82
Open:
$9.78
24h Volume:
37,647
Relative Volume:
0.71
Market Cap:
$200.19M
Revenue:
-
Net Income/Loss:
$-28.50M
P/E Ratio:
-5.3012
EPS:
-1.8128
Net Cash Flow:
$-25.87M
1W Performance:
-4.19%
1M Performance:
+6.72%
6M Performance:
-16.43%
1Y Performance:
+0.00%
1-Day Range:
$9.6001
$10.10
1-Week Range:
$9.57
$10.22
52-Week Range:
$5.44
$13.39
Satellos Bioscience Inc Stock (MSLE) Company Profile
Name
Satellos Bioscience Inc
Sector
Industry
Phone
-
Address
-
Compare MSLE vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MSLE
Satellos Bioscience Inc
|
9.61 | 208.73M | 0 | -28.50M | -25.87M | -1.8128 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Satellos Bioscience Inc Stock (MSLE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-06-26 | Initiated | Leerink Partners | Outperform |
| Mar-11-26 | Initiated | Cantor Fitzgerald | Overweight |
Satellos Bioscience Inc Stock (MSLE) Latest News
Satellos Bioscience Sets Up US$50 Million U.S. At-the-Market Share Sales Facility - TipRanks
Satellos Bioscience (MSLE) enters $50M at-the-market share deal - Stock Titan
Satellos Bioscience Inc. Stock 12‑Month Price Target Cut to $21.78, Implies 122% Upside - TradingView
Why Satellos Bioscience Inc. stock is sliding today - Wealth Awesome
Satellos Bioscience Inc. Stock 12‑Month Price Target Cut to $21.92, Implies 123% Upside - TradingView
Satellos Bioscience: Q2 Earnings Snapshot - AOL.com
Satellos Bioscience Posts Larger Q2 2026 Loss on Higher R&D but Doubles Equity Base - TipRanks
Satellos Q2 loss widens to $11.7M, EPS misses estimates - scanx.trade
Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress - The Manila Times
Satellos Bioscience (NASDAQ: MSLE) ramps Duchenne R&D and strengthens cash - Stock Titan
Satellos Bioscience Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Satellos reports stable strength in four-adult Duchenne study - Stock Titan
Satellos Bioscience (MSLE) Institutional Ownership 2026 - MarketBeat
Satellos Bioscience Files For Mixed Shelf Of Up To $300 Million - TradingView
Satellos Bioscience Inc. (TSX:MSCL) Stock Declines as Biotech Risks and Funding Concerns Pressure Sentiment - kalkine.ca
Satellos Bioscience (TSX:MSCL): Can This Toronto Biotech Actually Regrow Muscle in Duchenne Patients? - kalkine.ca
Satellos Bioscience Stock Climbs as Duchenne Therapy Data Strengthen Bullish Momentum: Can TSX:MSCL Extend Its Recovery? - kalkine.ca
Satellos Wins FDA Fast Track for SAT-3247 as Its Duchenne Programme Enters a Catalyst-Rich Second Half - kalkine.ca
Why Satellos Bioscience Inc. stock is skyrocketing today - Wealth Awesome
Satellos Bioscience Inc expected to post a loss of 53 cents a shareEarnings Preview - TradingView
Satellos Bioscience Inc. (TSX:MSCL) Faces Crucial Smallcap Tests - Kalkine Media
Why Satellos Bioscience Inc. stock fell yesterday - Wealth Awesome
Satellos Bioscience Ord Shs (MSLE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Satellos Bioscience Ord Shs (MSLE) Institutional Confidence - tradingkey.com
Satellos Bioscience Inc Revenue Breakdown – LSX:A4211W - TradingView
Why Satellos Bioscience Inc. stock surged yesterday - Wealth Awesome
What's Going On With Satellos Bioscience Inc. Stock Wednesday? - Wealth Awesome
Why Satellos Bioscience Inc. stock is plummeting today - Wealth Awesome
Independent Director of Satellos Bioscience Picks Up 1.9% More Stock - simplywall.st
Satellos Bioscience Inc. (MSLE) Q1 2026 Earnings: Wider-Than-Expected Loss Reflects R&D Spending; Stock Rises Despite EPS MissGross Profit Margin - dars.gov.et
What's Going On With Satellos Bioscience Inc. Stock Thursday? - Wealth Awesome
Satellos Bioscience Inc. (MSLE) Q1 2026 Earnings: EPS Misses Estimates as Development Costs ContinueEarnings Beat Alert - dars.gov.et
What is HC Wainwright's Forecast for MSLE FY2029 Earnings? - MarketBeat
Price to book forward of Satellos Bioscience Inc – SWB:0IT - TradingView
Satellos Bioscience Inc.Common Stock (MSLE) Stock Price, News, Quote & History - FinancialContent
Satellos Bioscience (MSLE) Extends Gains: Shares Up 3.71% as Resistance at $10.28 LoomsSafe Entry Stocks - dars.gov.et
Satellos Bioscience DMD Drug Shows Early Promise in 6-Month Study Update - TradingView
Satellos Bioscience Delivers Promising DMD Data With Fast Track Win - Streetwise Reports
Biotech With Muscle Disease Drug Uncovers Results in Trial Data - Streetwise Reports
H.C. Wainwright Maintains Satellos Bioscience(MSLE.US) With Buy Rating, Raises Target Price to $18 - Moomoo
Satellos Bioscience stock price target raised to $18 by H.C. Wainwright on trial data By Investing.com - Investing.com India
Satellos Bioscience stock price target raised to $18 by H.C. Wainwright on trial data - Investing.com South Africa
Satellos reports six-month Phase II data for SAT-3247 in Duchenne muscular dystrophy - The Pharma Letter
HC Wainwright Forecasts Strong Price Appreciation for Satellos Bioscience (NASDAQ:MSLE) Stock - MarketBeat
MSLE Maintained by HC Wainwright & Co. -- Price Target Raised to $18.00 - GuruFocus
Satellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, Increased Effort, Stable Strength, Lower CK and Favorable Safety Profile in DMD Adults Treated with SAT-3247 - Investing News Network
Phase II DMD Trailhead data hike Satellos’ stock - bioworld.com
Satellos Bioscience's Share Rise After SAT-3247 Shows Positive Results for Duchenne MD - Moomoo
Satellos reports positive TRAILHEAD data for DMD drug - grafa.com
Satellos Bioscience Duchenne Drug Candidate's Interim Data Boosts Confidence - Yahoo Finance
Satellos Bioscience Posts Encouraging Six-Month TRAILHEAD Data in Adult DMD Patients - TipRanks
Satellos Bioscience Inc Stock (MSLE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):